Safety and Efficacy of Olanzapine (LY170053) in the Long-Term Treatment for Patients With Bipolar I Disorder, Depressed.

Trial Profile

Safety and Efficacy of Olanzapine (LY170053) in the Long-Term Treatment for Patients With Bipolar I Disorder, Depressed.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2011

At a glance

  • Drugs Olanzapine (Primary)
  • Indications Bipolar I disorders
  • Focus Adverse reactions; Registrational
  • Sponsors Eli Lilly
  • Most Recent Events

    • 27 Sep 2010 Actual patient number is 101 as according to ClinicalTrials.gov.
    • 27 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 27 Sep 2010 Status changed from active, no longer recruiting to completed as according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top